In the development of the drug Zeqmelit/ISICORT®, AcuCort has managed to combine the benefits of the well-proven substance dexamethasone and the patented user-friendly oral film for quick accessibility and relief in acute situations such as severe and acute allergic reactions.

The registration process for the Nordic market is ongoing and the drug is now approved in Denmark and Sweden. Intensive work is underway on registration applications for other priority markets.  AcuCort’s goal is to commercialize Zeqmelit/ISICORT® globally, i.e. in the EU, the US and in selected key markets.

“AcuCort has passed another important milestone as the company’s first innovative drug is now approved also in Denmark. This is very gratifying and creates good conditions for a continued positive development of the company. I am optimistic about the upcoming commercialization and our continued growth journey,” says Jonas Jönmark, CEO of AcuCort AB.

This information is information that AcuCort AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person below, on August 16, 2022.